Welcome to CDC Stacks | CDC recommends suspension of the routine use of the third and fourth doses of pneumococcal conjugate vaccine (Prevnar®) - 25098 | Health Alert Network (HAN)
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
CDC recommends suspension of the routine use of the third and fourth doses of pneumococcal conjugate vaccine (Prevnar®)
  • Published Date:
    3/2/04
  • Source:
    HAN ; 187
  • Language:
    English
Filetype[PDF - 750.63 KB]


Details:
  • Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
  • Series:
    HAN ; 187
  • Document Type:
  • Description:
    Tuesday, March 02, 2004, 16:26 EST (04:26 PM EST)

    CDCHAN-00187-2004-03-02-ADV-N

    All health-care providers should temporarily suspend routine use of both the third and fourth doses of pneumococcal conjugate vaccine (PCV7), the Centers for Disease Control and Prevention (CDC) recommended today. Children at increased risk of severe disease should continue to receive the full, routine, four-dose series.

    CDC took the action in consultation with the American Academy of Family Physicians (AAFP), the American Academy of Pediatrics (AAP), and the Advisory Committee on Immunization Practices (ACIP), to most effectively use the limited, available doses of until the manufacturer can restore full production. Wyeth Vaccines, the sole manufacturer in the United States, markets PCV7 under the trade name Prevnar®.

  • Supporting Files:
    No Additional Files